ProQR Therapeutics N.V. Holds 2024 Annual General Meeting

TL;DR

ProQR held its 2024 shareholder meeting on May 22nd, results are in.

AI Summary

ProQR Therapeutics N.V. held its 2024 annual general meeting of shareholders on May 22, 2024. The meeting results, which are the subject of this 6-K filing, were disclosed on this date. The company is based in Leiden, The Netherlands.

Why It Matters

This filing provides an update on the outcomes of ProQR's annual shareholder meeting, which can influence investor sentiment and future corporate actions.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of meeting results and does not contain new financial or operational information that would significantly alter risk.

Key Players & Entities

• ProQR Therapeutics N.V. (company) — Filer of the 6-K report
• May 22, 2024 (date) — Date of the annual general meeting
• Leiden, The Netherlands (location) — Company's principal executive offices

FAQ

Filing Documents

• tm2415285d1_6k.htm (6-K) — 16KB
• 0001104659-24-064273.txt ( ) — 17KB

: Adoption of the annual accounts, including the appropriation of net result, for the financial year 2023

Item 3 : Adoption of the annual accounts, including the appropriation of net result, for the financial year 2023. ProQR shareholders approved the adoption of the annual accounts, including the appropriation of net result, for the financial year 2023. Agenda Item 4 : Release from liability of the members of the Management Board with respect to the performance of their management during the financial year 2023. ProQR shareholders approved the release from liability of the members of the Management Board with respect to the performance of their management during the financial year 2023. Agenda Item 5 : Release from liability of the members of the Supervisory Board with respect to the performance of their supervision during the financial year 2023. ProQR shareholders approved the release from liability of the members of the Supervisory Board with respect to the performance of their supervision during the financial year 2023. Agenda

: Appointment of Gerard Platenburg as Management Board member

Item 6 : Appointment of Gerard Platenburg as Management Board member. ProQR shareholders approved the appointment of Gerard Platenburg as Management Board member. Agenda

: Appointment of Martin Maier, PhD, as Supervisory Board member

Item 7 : Appointment of Martin Maier, PhD, as Supervisory Board member. ProQR shareholders approved the appointment of Martin Maier, PhD, as Supervisory Board member. Agenda

: Re-appointment of Dinko Valerio, PhD, as Supervisory Board member

Item 8 : Re-appointment of Dinko Valerio, PhD, as Supervisory Board member. ProQR shareholders approved the re-appointment of Dinko Valerio, PhD, as Supervisory Board member. Agenda

: Re-appointment of James Shannon, MD, as Supervisory Board member

Item 9 : Re-appointment of James Shannon, MD, as Supervisory Board member. ProQR shareholders approved the re-appointment of James Shannon, MD, as Supervisory Board member. Agenda

: Appointment of KPMG Accountants N.V. as the Company’s external auditor for the financial year 2025

Item 10 : Appointment of KPMG Accountants N.V. as the Company’s external auditor for the financial year 2025. ProQR shareholders approved the appointment of KPMG Accountants N.V. as the Company’s external auditor for the financial year 2025. Agenda

: Authorization of the Management Board to issue ordinary shares

Item 11 : Authorization of the Management Board to issue ordinary shares. ProQR shareholders approved the authorization of the Management Board to issue ordinary shares. Agenda

: Authorization of the Management Board to acquire ordinary shares in the capital of the Company

Item 12 : Authorization of the Management Board to acquire ordinary shares in the capital of the Company. ProQR shareholders approved the authorization of the Management Board to acquire ordinary shares in the capital of the Company. Agenda

: Change of the board structure

Item 13 : Change of the board structure. ProQR shareholders approved the change of the board structure.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PROQR THERAPEUTICS N.V. Date: May 22, 2024 By: /s/ René Beukema René Beukema Chief Corporate Development Officer and General Counsel

View Full Filing

View this 6-K filing on SEC EDGAR